Intermediate Strengths and Inflated Prices: The Story of Transdermal Fentanyl Patches

S. M.Qasim Hussaini, Ramy Sedhom, Stacie B. Dusetzina, Arjun Gupta

Research output: Contribution to journalArticlepeer-review

2 Scopus citations


In 2015, Mylan pharmaceuticals received final approval from the Food and Drug Administration for its Supplemental Abbreviated New Drug Application and introduced three new intermediate strengths of transdermal fentanyl patches to the U.S. drug market.1 With this approval, Mylan added 37.5 , 62.5, and 87.5 mcg/hr strength patches to existing 12, 25, 50, 75, and 100 mcg/hr strength patches. Today, these intermediate strength patches cost many times more than older strengths. In this commentary, we discuss the clinical implications of intermediate strengths of the fentanyl patch, explore mechanisms for price differences, and offer practice-based and policy solutions to address these differences.

Original languageEnglish (US)
Pages (from-to)1335-1337
Number of pages3
JournalJournal of palliative medicine
Issue number9
StatePublished - Sep 1 2022

Bibliographical note

Publisher Copyright:
© Copyright 2022, Mary Ann Liebert, Inc., publishers 2022.


  • cancer
  • fentanyl
  • financial toxicity
  • pain
  • policy

PubMed: MeSH publication types

  • Journal Article


Dive into the research topics of 'Intermediate Strengths and Inflated Prices: The Story of Transdermal Fentanyl Patches'. Together they form a unique fingerprint.

Cite this